HSP90A inhibition promotes anti-tumor immunity by reversing multi-modal resistance and stem-like property of immune-refractory tumors

HSP90A inhibition promotes anti-tumor immunity by reversing multi-modal resistance and stem-like property of immune-refractory tumors

Nanog can confer resistance to cancer immunotherapy by promoting AKT activity. Here, the authors demonstrate that HSP90A is a Nanog target that stabilizes the AKT coactivator TCL1, thereby activating AKT, and that HSP90A inhibition can enhance the anti-tumor efficacy of adoptive T cell transfer and...

Full description

Bibliographic Details
Main Authors: Kwon-Ho Song, Se Jin Oh, Suyeon Kim, Hanbyoul Cho, Hyo-Jung Lee, Joon Seon Song, Joon-Yong Chung, Eunho Cho, Jaeyoon Lee, Seunghyun Jeon, Cassian Yee, Kyung-Mi Lee, Stephen M. Hewitt, Jae-Hoon Kim, Seon Rang Woo, Tae Woo Kim
Format: Article
Language:English
Published: Nature Portfolio 2020-01-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-019-14259-y

Internet

https://doi.org/10.1038/s41467-019-14259-y

Similar Items